A R T I C L E
N AT URE CO M MU N ICAT I ON S | D O I: 10 . 10 38/s4 14 67 -0 1 6-000 9- 6
Statistical analysis. Unless specified, all data were obtained from at least triplicate
samples and represent at least three independent experiments and presented as
mean ± s.e.m. Graphs were constructed using GraphPad Prism 4.0 (GraphPad
Software). Where applicable, statistical differences were tested by unpaired
Student’s t-test and were considered significant for P < 0.05.
26. Grosser, T., Yu, F. & FitzGerald, G. A. Emotion recollected in tranquility:
lessons learned from the COX-2 saga. Annu. Rev. Med. 61, 17–33 (2010).
27. Dogne, J.-M., Supuran, C. T. & Pratico, D. Adverse cardiovascular effects of the
coxibs. J. Med. Chem. 48, 2251–2257 (2005).
28. Yu, Y. et al. Vascular COX-2 modulates blood pressure and thrombosis in mice.
Sci. Transl. Med. 4, 132ra54 (2012).
2
9. Bhardwaj, A., Huang, Z., Kaur, J. & Knaus, E. E. Rofecoxib analogues
Data availability. The authors declare that all data supporting the findings of this
study are available in the article and in the supplementary information file.
Additional information are available from the corresponding author upon request.
possessing a nitric oxide donor sulfohydroxamic acid (SO NHOH)
2
cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and
biological evaluation as anti-inflammatory agents. Chem. Med. Chem. 7, 62–67
(
2012).
Received: 1 November 2015 Accepted: 14 November 2016
3
0. Luong, C. et al. Flexibility of the NSAID binding site in the structure of human
cyclooxygenase-2. Nat. Struct. Biol. 3, 927–933 (1996).
3
1. Vecchio, A. J., Orlando, B. J., Nandagiri, R. & Malkowski, M. G. Investigating
substrate promiscuity in cyclooxygenase-2: the role of Arg-120 and residues
lining the hydrophobic groove. J. Biol. Chem. 287, 24619–24630 (2012).
2. Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click chemistry: diverse chemical
function from a few good reactions. Angew. Chem. Int. Ed. 40, 2004–2021
(2001).
3
References
1.
2.
3.
4.
5.
6.
Smith, W. L., Urade, Y. & Jakobsson, P. J. Enzymes of the cyclooxygenase
pathways of prostanoid biosynthesis. Chem. Rev. 111, 5821–5865 (2011).
van der Donk, W. A., Tsai, A. L. & Kulmacz, R. J. The cyclooxygenase reaction
mechanism. Biochemistry. 41, 15451–15458 (2002).
Blobaum, A. L. & Marnett, L. J. Structural and functional basis of
cyclooxygenase inhibition. J. Med. Chem. 50, 1425–1441 (2007).
Marnett, L. J. The COXIB experience: a look in the rearview mirror. Annu. Rev.
Pharmacol. Toxicol. 49, 265–290 (2009).
Smith, W. L., Garavito, R. M. & DeWitt, D. L. Prostaglandin endoperoxide H
synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 271, 33157–33160 (1996).
Kurumbail, R. G. et al. Structural basis for selective inhibition of
cyclooxygenase-2 by anti-inflammatory agents. Nature. 384, 644–648
33. Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise
Huisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of
azides and terminal alkynes. Angew. Chem., Int. Ed. 41, 2596–2599 (2002).
34. Wu, H., Yang, J., Seckute, J. & Devaraj, N. K. In situ synthesis of alkenyl
tetrazines for highly fluorogenic bioorthogonal live-cell imaging probes. Angew.
Chem.Int. Ed. 126, 5915–5919 (2014).
35. Mind, M. L. et al. A “click chemistry” approach to the efficient synthesis of
multiple imaging probes derived from a single precursor. Bioconjugate Chem
20, 1940–1949 (2009).
36. Thirumurugan, P., Matosiuk, D. & Jozwiak, K. Click chemistry for drug
development and diverse chemical–biology applications. Chem. Rev. 113,
4905–4979 (2013).
(
1996).
7
8
9
.
.
.
Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural,
cellular, and molecular biology. Annu. Rev. Biochem. 69, 145–182 (2000).
Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: the biology
of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56, 387–437 (2004).
Chandrasekharan, N. V. et al. COX-3, a cyclooxygenase-1 variant inhibited by
acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and
expression. Proc. Natl Acad. Sci. USA 99, 13926–13931 (2002).
37. Lang, K. & Chin, J. W. Cellular incorporation of unnatural amino acids and
bioorthogonal labeling of proteins. Chem. Rev. 114, 4764–4806 (2014).
38. Dirks, A. J. et al. From (bio)molecules to biohybrid materials with the click
chemistry approach. QSAR Comb. Sci. 26, 1200–1210 (2007).
39. El-Sagheer, A. H. & Brown, T. Click nucleic acid ligation: applications in
biology and nanotechnology. Acc. Chem. Res. 45, 1258–1267 (2012).
40. Di Antonio, M. et al. Selective RNA versus DNA g-quadruplex targeting by
in situ click chemistry. Angew. Chem. Int. Ed. 51, 11073–11078 (2012).
41. Hanson, S. R., Greenberg, W. A. & Wong, C.-H. Probing glycans with the
copper(I)-catalyzed [3+2] azide–alkyne cycloaddition. QSAR Comb. Sci. 26,
1243–1252 (2007).
1
0. Mitchell, J. A. & Warner, T. D. Cyclo-oxygenase-2: pharmacology, physiology,
biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 128,
1121–1132 (1999).
1
1
1
1
1
1
1
1. Ricciotti, E. & FitzGerald, G. A. Prostaglandins and inflammation. Arterioscler.
Thromb. Vasc. Biol. 31, 986–1000 (2011).
42. Rong, J. et al. Glycan imaging in intact rat hearts and glycoproteomic analysis
reveal the upregulation of sialylation during cardiac hypertrophy. J. Am. Chem.
Soc. 136, 17468–17476 (2014).
2. Wang, D. & DuBois, R. N. The role of anti-inflammatory drugs in colorectal.
Cancer Rev. Med 64, 131–144 (2013).
3. Wang, D. & DuBois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer. 10,
43. Mamidyala, S. K. & Finn, M. G. In situ click chemistry: probing the binding
landscapes of biological molecules. Chem. Soc. Rev. 39, 1252–1261 (2010).
44. Sharpless, K. B. & Manetsch, R. In situ click chemistry: a powerful means for
lead discovery. Expert Opin. Drug Discov. 1, 525–538 (2006).
45. Lewis, W. G. et al. Click chemistry in situ: acetylcholinesterase as a reaction
vessel for the selective assembly of a femtomolar inhibitor from an array of
building blocks. Angew. Chem. Int. Ed. 41, 1053–1101 (2002).
46. Krasinski, A. et al. In situ selection of lead compounds by click chemistry:
target-guided optimization of acetylcholinesterase inhibitors. J. Am. Chem. Soc.
127, 6686–6692 (2005).
181–193 (2010).
4. Meric, J.-B. et al. Cyclooxygenase-2 as target of anticancer drug development.
Crit. Rev. Oncol. Hematol. 59, 51–64 (2006).
5. Teismann, P. et al. Cyclooxygenase-2 is instrumental in Parkinson’s disease
neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473–5478 (2003).
6. Sorokin, A. Cyclooxygenase-2: potential role in regulation of drug efflux and
multidrug resistance phenotype. Curr. Pharm. Des. 10, 647–657 (2004).
7. Uddin, M. J. et al. Selective visualization of cyclooxygenase-2 in inflammation
and cancer by targeted fluorescent imaging agents. Cancer Res. 70, 3618–3627
(
2010).
47. Manetsch, R. et al. In situ click chemistry: enzyme inhibitors made to their own
specifications. J. Am. Chem. Soc. 126, 12809–12818 (2004).
1
8. Bhardwaj, A., Kaur, J., Wuest, F. & Knaus, E. E. Fluorophore-labeled
cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2
overexpression in cancer: synthesis and biological studies. ChemMedChem. 9,
48. Whiting, M. et al. Inhibitors of HIV-1 protease by using in situ click chemistry.
Angew. Chem. Int. Ed. 45, 1435–1439 (2006).
1
09–116 (2014).
49. Mocharla, V. P. et al. In situ click chemistry: enzyme-generated inhibitors of
carbonic anhydrase II. Angew. Chem. Int. Ed. 44, 116–120 (2005).
50. Wang, J. Y. et al. Integrated microfluidics for parallel screening of an in situ
click chemistry library. Angew. Chem. Int. Ed. 45, 5276–5281 (2006).
51. Srinivasan, R., Uttamchandani, M. & Yao, S. Q. Rapid assembly and in situ
screening of bidentate inhibitors of protein tyrosine phosphatases. Org. Lett. 8,
713–716 (2006).
52. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B. F. Activity-
based probes for the proteomic profiling of metalloproteases. Proc. Natl Acad.
Sci. USA 101, 10000–10005 (2004).
53. Sieber, S. A., Niessen, S., Hoover, H. S. & Cravatt, B. F. Proteomic profiling of
metalloprotease activities with cocktails of active-site probes. Nat. Chem. Biol.
2, 274–281 (2006).
54. Grimster, N. P. et al. Generation of candidate ligands for nicotinic acetylcholine
receptors via in situ click chemistry with a soluble acetylcholine binding protein
template. J. Am. Chem. Soc. 134, 6732–6740 (2012).
1
9. Tietz, O. et al. PET imaging of cyclooxygenase-2 (COX-2) in a colon cancer
model. EJNMMI Res. 6, 37 (2016).
0. Vosooghi, M. et al. The discovery and development of cyclooxygenase-2
inhibitors as potential anticancer therapies. Expert Opin. Drug Discov 9,
2
2
55–267 (2014).
2
2
1. Xu, L. et al. COX-2 inhibition potentiates antiangiogenic cancer therapy
and prevents metastasis in preclinical models. Sci. Transl. Med. 6, 242ra84
(
2014).
2. Salehifar, E. et al. The use of cyclooxygenase-2 inhibitors for improvement
of efficacy of radiotherapy in cancers. Drug Discov. Today. 21, 654–662
(
2016).
2
2
2
3. Marnett, L. J. Inflammation and cancer: chemical approaches to mechanisms,
imaging, and treatment. J. Org. Chem. 77, 5224 (2012).
4. Flower, R. J. The development of COX2 inhibitors. Nat. Rev. Drug Discov. 2,
179–191 (2003).
5. Uddin, M. J. et al. Trifluoromethyl fluorocoxib A detects cyclooxygenase-2
expression in inflammatory tissues and human tumor xenografts. ACS Med.
Chem. Lett. 5, 446–450 (2014).
55. Hirose, T. et al. Chitinase inhibitors: extraction of the active framework from
natural argifin and use of in situ click chemistry. J. Antibiot. 62, 277–282
(2009).
1
2
N A TU RE CO MMU N I C AT I ON S |8:
1